跳至主要内容
临床试验/NCT05336110
NCT05336110已完成不适用

Assessment of the Impact of the Postponement of Surgery on the Postoperative Morbidity After Sars-cov-2 Infection in 2022

Société Française d'Anesthésie et de Réanimation40 个研究点 分布在 1 个国家目标入组 5,189 人开始时间: 2022年3月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
5,189
试验地点
40
主要终点
Composite endpoint, that consist of respiratory morbidity associated with occurrence of respiratory events and use or prolongation of mechanical ventilation.

研究概览

简要总结

The deployment of vaccination against SARS-CoV-2 from 2021 led to a modification in June 2021of previous recommendations concerning the postponing scheduled surgery suggesting local adaptations of this delay if epidemic developments appear. Today, the evolutions of the pandemic make these recommendations obsolete and impose the updating of the data produced during the first epidemic wave of 2020. Among these evolutions, the two most important are the existence of a large vaccination coverage on the one hand and the emergence of variants of lesser severity on the other hand

详细描述

Previous studies performed during the first COVID-19 epidemic wave in the first half of 2020 led to the recommendation, after taking into account the individual risk-benefit balance, of postponing scheduled surgery for ideally at least 6 completed weeks in a patient with a positive preoperative SARS-CoV-2 PCR.

The deployment of vaccination against SARS-CoV-2 from 2021 led to a modification of these recommendations in June 2021 suggesting local adaptations of this delay if epidemic developments appear. Today, the evolutions of the pandemic make these recommendations obsolete and impose the updating of the data produced during the first epidemic wave of 2020. Among these evolutions, the two most important are the existence of a large vaccination coverage on the one hand and the emergence of variants of lesser severity on the other hand

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult patients,
  • •Surgery performed in the operating room under general or locoregional anesthesia.
  • •Result of the preoperative SARS-COV-2 diagnostic test available on the day of the procedure or within 48 hours of the surgery.
  • •Emergency or scheduled surgery
  • •All surgical indications will be eligible with the exception of certain surgeries

排除标准

  • •Minor patient
  • •Pregnant patient
  • •Surgery or an intervention performed outside the operating room
  • •Patient operated under sedation alone,
  • •Patient under guardianship or curatorship
  • •Patient without social protection
  • •Patient previously included in this study
  • •Patient without preoperative COVID-19 status on day of surgery and not diagnosable within 48 postoperative hours
  • •Patient whose immediate postoperative follow-up is planned in a structure other than those where the inclusion was made

结局指标

主要结局

Composite endpoint, that consist of respiratory morbidity associated with occurrence of respiratory events and use or prolongation of mechanical ventilation.

时间窗: up to 30 postoperative days.

The primary endpoint will be a composite endpoint, that consist of respiratory morbidity associated with occurrence of pneumonia (bacterial or viral), acute respiratory distress, symptomatic pulmonary embolism (i.e. having led to a diagnostic procedure and a treatment), and postoperative prolongation of mechanical ventilation or the use of unscheduled, during the postoperative hospital stay and within the limit of 30 postoperative days.

次要结局

  • Secondary Outcome Measures include hospital mortality,(up to 30 postoperative days.)
  • Secondary Outcome Measures include non-respiratory infection or septic shock,(up to 30 postoperative days.)
  • Secondary Outcome Measures include length of hospital stay and length of critical care stay.(up to 30 postoperative days.)
  • Secondary Outcome Measures include the need for re-hospitalization during the first 30 days after surgery(up to 30 postoperative days.)
  • Secondary Outcome Measures include mortality at D30,(up to 30 postoperative days.)
  • Secondary Outcome Measures include the occurrence of a deep vein thrombosis,(up to 30 postoperative days.)
  • Secondary Outcome Measures include non-respiratory infection and septic shock,(up to 30 postoperative days.)

研究者

发起方
Société Française d'Anesthésie et de Réanimation
申办方类型
Other
责任方
Sponsor

研究点 (40)

Loading locations...

相似试验